Table 2.
Univariate and Multivariate Fine-Gray regression model for HG recurrence and progression to MIBC or metastatic disease.
| High-Grade Recurrence | Progression to MIBC or Metastatic Disease | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||||||
| Characteristic | SHR | 95%CI | p-value | SHR | 95%CI | p-value | SHR | 95%CI | p-value | SHR | 95%CI | p-value |
| Age at diagnosis | ||||||||||||
| Age≤70 | 1.00 | . | 1.00 | . | 1.00 | . | 1.00 | . | ||||
| Age>70 | 1.07 | 0.78–1.45 | 0.7 | 1.05 | 0.77–1.44 | 0.7 | 1.75 | 1.01–3.04 | 0.047 | 1.57 | 0.87–2.81 | 0.13 |
| BMI | 1.01 | 0.98–1.03 | 0.6 | 0.94 | 0.91–0.97 | 0.001 | 0.94 | 0.91–0.98 | 0.002 | |||
| Gender | ||||||||||||
| Male | 1.00 | . | 1.00 | . | ||||||||
| Female | 1.19 | 0.82–1.73 | 0.3 | 0.82 | 0.40–1.69 | 0.6 | ||||||
| Smoker | ||||||||||||
| Never | 1.00 | . | 1.00 | . | 1.00 | . | ||||||
| Current/Past | 0.79 | 0.58–1.09 | 0.15 | 0.77 | 0.56–1.07 | 0.12 | 0.94 | 0.52–1.68 | 0.8 | |||
| Grade | ||||||||||||
| Low | 1.00 | . | 1.00 | . | 1.00 | . | 1.00 | . | ||||
| High | 8.26 | 2.02–33.77 | 0.003 | 13.49 | 1.86–97.78 | 0.01 | 4.88 | 0.68–34.99 | 0.11 | 3.36 | 0.45–24.96 | 0.23 |
| Stage of entry TURBT | ||||||||||||
| Ta | 1.00 | . | 1.00 | . | 1.00 | . | 1.00 | . | ||||
| Tis | 2.32 | 1.36–3.97 | 0.002 | 1.64 | 0.89–3.02 | 0.11 | 1.94 | 0.63–5.91 | 0.24 | 1.49 | 0.45–4.94 | 0.5 |
| T1 | 1.89 | 1.35–2.66 | <0.001 | 1.92 | 1.34–2.75 | <0.001 | 2.38 | 1.29–4.39 | 0.005 | 2.94 | 1.51–5.72 | 0.001 |
| Tumor | ||||||||||||
| Primary | 1.00 | . | 1.00 | . | 1.00 | . | 1.00 | . | ||||
| Recurrent | 1.32 | 0.96–1.82 | 0.08 | 1.73 | 1.23–2.43 | 0.001 | 1.58 | 0.99–2.74 | 0.1 | 2.40 | 1.34–4.30 | 0.003 |
| Variant Histology | ||||||||||||
| No | 1.00 | . | 1.00 | . | 1.00 | . | ||||||
| Yes | 0.51 | 0.20–1.29 | 0.15 | 0.50 | 0.19–1.31 | 0.16 | 1.06 | 0.25–4.41 | 0.9 | |||
| Size>3 cm | ||||||||||||
| No | 1.00 | . | 1.00 | . | ||||||||
| Yes | 1.09 | 0.79–1.51 | 0.6 | 0.77 | 0.43–1.39 | 0.4 | ||||||
| LVI | ||||||||||||
| No | 1.00 | . | 1.00 | . | 1.00 | . | ||||||
| Yes | 1.60 | 0.58–4.47 | 0.4 | 4.32 | 0.91–19.65 | 0.065 | 4.06 | 0.84–19.67 | 0.08 | |||
| CIS in entry tumor | ||||||||||||
| No | 1.00 | . | 1.00 | . | 1.00 | . | 1.00 | . | ||||
| Yes | 1.52 | 1.11–2.08 | 0.008 | 1.19 | 0.83–1.71 | 0.3 | 1.39 | 0.80–2.43 | 0.24 | 1.03 | 0.55–1.93 | 0.9 |
| Focality | ||||||||||||
| Single | 1.00 | . | 1.00 | . | 1.00 | . | 1.00 | . | ||||
| Multiple | 1.32 | 0.96–1.80 | 0.08 | 1.19 | 0.86–1.65 | 0.3 | 1.41 | 0.81–2.45 | 0.23 | 1.28 | 0.69–2.37 | 0.4 |
| Peri-operative Intravesical Chemotherapy | ||||||||||||
| No | 1.00 | . | 1.00 | . | ||||||||
| Yes | 0.95 | 0.58–1.54 | 0.8 | 0.87 | 0.36–2.09 | 0.8 | ||||||
MIBC: Muscle-invasive bladder cancer; SHR: Sub-standardized Hazard ratio; CI: confident interval; BMI: Body-mass index; TURBT: Transurethral resection of the bladder; LVI: Lymphovascular invasion, CIS: carcinoma in situ.